It is the second licensing deal involving siRNA between GSK and a Chinese biotech in the last few months, coming after the UK ...

Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US ...

The closed sites include some that came with its $1.25 billion takeover of CureVac last year, and BioNTech has said it hopes ...

While still making up a modest part of that total, oral Wegovy (semaglutide) performed better than expected since its launch ...

Bristol Myers Squibb has reached for its wallet to avoid being left behind in the race to develop a new class of bispecific antibodies for cancer that have been billed as the next big thing in ...

Bristol Myers Squibb and Pfizer have launched an online programme to sell their blockbuster anticoagulant Eliquis directly to patients, following in the footsteps of Eli Lilly and Novo Nordisk in a ...

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series B backed by recent partner Eli Lilly. SanegeneBio, a biotech company with ...

Indian pharma group Wockhardt has completed a pre-filing meeting with the FDA and hopes to submit its new antibiotic Zaynich in the US and Europe later this year, eyeing a possible launch in fiscal ...

In a landmark procedure performed at Massachusetts General Hospital (MGH) on 25 th January 2025, a 66-year-old man with end-stage renal disease (ESRD) received a genetically modified pig kidney, ...

The FDA has added a warning label to bluebird bio's Skysona, after launching an investigation into cases of blood cancer in patients treated with the ex vivo gene therapy last November. Skysona ...

AstraZeneca's hopes of a big new indication for respiratory drug Fasenra in chronic obstructive pulmonary disease (COPD) have been dashed by a negative phase 3 trial. The RESOLUTE study of IL-5 ...

Navdeep "Navi" Chadha is co-founder and CTO of Axtria, a global provider of AI-powered data analytics and cloud software for ...